PBLA - Earnings announcements

MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50956 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50956Webcast Replay: https://www.webc

MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50531Webcast Replay: https://www.webcas

MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 195310Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/49978 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 49978Webcast Replay: 

MINNEAPOLIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2023. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2023 and Recent Highlights Collaborations Divestiture of assets within eflornithine (DFMO) pediatric neuroblastoma program to US WorldMeds® for an upfront payment of $400,000 and contingent payments totaling up to an additional $9.1 million. Clinical The independent Data Safety Monitor

MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 9, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023. Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.Date:  November 9, 2023Time: 4:30 PM Eastern TimeParticipant Numbers: Toll Free: 888-506-0062; Code: 100225International: 973-528-0011; Code: 100225Webcast: https://www.webcaster4.com/Webcast/Page

MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 10, 2023, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023. Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.Date: Thursday, August 10, 2023Time: 4:30 PM Eastern TimeParticipant Numbers: Toll Free: 888-506-0062; Code: 681215International: 973-528-0011; Code: 681215Webcast: https://www.webcaster4.com/Webca

MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 4, 2023, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2023. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: Thursday, May 04, 2023 Time: 4:30 PM Eastern Time Participant Numbers: Toll Free: 888-506-0062; Code: 130038 International: 973-528-0011; Code: 130038 Webcast: https://www.webcaster4.com/W

MINNEAPOLIS, March 08, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 16, 2023, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2022. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 116790Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/47782 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 47782Webca

MINNEAPOLIS, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 10, 2022, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2022. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: November 10, 2022Time: 4:30 PM Eastern Time Participant Numbers:Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 598956 Webcast Link: h

MINNEAPOLIS, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2022. Management is hosting an earnings conference call today at 4:30 p.m. ET. The second quarter was marked by meaningful progress. Q2 and Recent Highlights: First Patient Enrolled in its Aspire Trial.Received approval from the Australian Human Research Ethics Committee (HREC) to expand the company's global clinical trial to Australia.Closed on the acquisition of Cancer Prevention Phar

MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 15, 2022, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2022. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: August 15, 2022Time: 4:30 PM Eastern TimeToll Free: 888-506-0062; Access Code: 429849International: 973-528-0011; Access Code: 429849Webcast Link: https://www.webcaster4.com/Webca

MINNEAPOLIS, May 12, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today provides a business update and reports financial results for the quarter ended March 31, 2022. Management is hosting an earnings call today at 4:30 p.m. ET. The first quarter was marked by meaningful progress. Q1 and Recent Highlights: Agreed to acquire Cancer Prevention Pharmaceuticals, Inc. (CPP). The combined entity would target an estimated $5 billion aggregated market opportunity upon closing.Hosted a virtual R&D Day on the company's investigational drug, SBP-101, as a polyamine metabolis

MINNEAPOLIS, April 27, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, will host an R&D call on Tuesday, May 03, 2022 at 9:00 AM Eastern Time. Panbela's management team will be joined by leading experts for a deep dive on the company's investigational drug, SBP-101, as a polyamine metabolism modulator in ovarian cancer. Conference Call Information Event Date: Tuesday, May 03, 2022 - 9:00 AM Eastern Time Participant Numbers: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 365401 Event Link: https://www.webcaster4.com/

MINNEAPOLIS, April 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it will host a conference call on May 12, 2022 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2022. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: May 12, 2022Time: 4:30 PM Eastern TimeToll Free: 888-506-0062; Access Code: 824126International: 973-528-0011; Access Code: 824126 The call will also be available over the Internet and ac

MINNEAPOLIS, March 08, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it will host a conference call on March 24, 2022 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2021. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: March 24, 2022Time: 4:30 PM Eastern TimeToll Free: 888-506-0062; Access Code: 461101International: 973-528-0011; Access Code: 461101 The call will also be available over the Internet and ac

MINNEAPOLIS , Oct. 25, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it will host a conference call on November 10, 2021, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2021. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: November 10, 2021Time: 4:30 PM Eastern TimeToll Free: 877-545-0523; Access Code: 559201International: 973-528-0016 The call will also be available over the Internet and accessible at: 

MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today provided a business update and reported financial results for the quarter ended June 30, 2021. Management is hosting an earnings call today at 4:30 p.m. ET.  The second quarter 2021 was marked by meaningful clinical progress. Recent Highlights Issue Notification for patent US 11,098,005 titled "METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL". A novel process for the production of our lead investigational product SBP-101, reduces the number of synthetic s

MINNEAPOLIS, July 28, 2021 (GLOBE NEWSWIRE) --   Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that it will host a conference call on August 11, 2021, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2021.  Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: August 11, 2021 Time: 4:30 PM Eastern Time Toll Free: 877-407-9205 International: 201-689-8054 The call will also be available over the Internet and accessible at: https://www.webcas

MINNEAPOLIS, May 12, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today provides a business update and reports financial results for the quarter ended March 31, 2021. Management is hosting an earnings call today at 4:30 p.m. ET.  The first quarter 2021 was marked by meaningful clinical progress. Q1 and Recent Highlights Abstract accepted with poster presentation at American Society of Clinical Oncology (ASCO) Annual Meeting June 4-8, 2021.Partial clinical hold lifted from the company's Phase 1 first-line study of SBP-101.Research agreement entered